Burden of spasticity among patients and caregivers: Results of a multinational survey

Patel, Atul T.; Wein, Theodore; Bahroo, Laxman; Wilczynski, Ophélie; Rios, Carl D; Murie-Fernández, Manuel

doi:10.1016/j.toxicon.2018.11.214

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, limb spasticity has a detrimental impact not only on patients but also on their caregivers. Fulfilling caregiving responsibilities often necessitates reduced work hours or even resignation from employment, resulting in financial difficulties [ 9 ]. Caregivers frequently experience absenteeism and presenteeism, contributing to the overall caregiving load [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

A Cost-Effectiveness and Budget Impact Analysis of AbobotulinumtoxinA in Greece

Nomikos,

Eleftheriou,

Athanasakis

2023

Toxins

View full text Add to dashboard Cite

This study aimed to assess the cost-effectiveness of abobotulinumtoxinA (aboBoNT-A) plus Best Supportive Care (BSC) compared with BSC alone for managing limb spasticity in adult patients in Greece, as well as to conduct a budget impact analysis of the introduction of aboBoNT-A in the Greek healthcare system compared to onabotulinumtoxinA (onaBoNT-A). Clinical studies were utilized to extract data on drug efficacy and patients’ utility, while cost data were collected from Greek sources. The results of the study showed that aboBoNT-A plus BSC was a cost-effective treatment option for both upper and lower limb spasticity in adult patients compared to BSC. Additionally, introducing aboBoNT-A into the Greek healthcare system resulted in cost savings in pharmaceutical spending over a 5-year period. The findings suggest that incorporating aboBoNT-A into the Greek healthcare system could improve patient access to treatment and healthcare resource efficiency, as it is a more economical option compared to onaBoNT-A.

show abstract

Section: Introductionmentioning

confidence: 99%

A Cost-Effectiveness and Budget Impact Analysis of AbobotulinumtoxinA in Greece

Nomikos,

Eleftheriou,

Athanasakis

2023

Toxins

View full text Add to dashboard Cite

show abstract

“…Spastic hypertonia (hyperreflexia called “spasticity” and elevated involuntary muscle tone) can cause patient discomfort, impair sleep, and make activities like dressing the upper body difficult (Patel et al, 2019 ). Spastic hypertonia can increase when the limb is in use or when medication treatments, like Botulinum toxin, are wearing off (Sommerfeld et al, 2004 ).…”

Section: Introductionmentioning

confidence: 99%

Relief of post-stroke spasticity with acute vibrotactile stimulation: controlled crossover study of muscle and skin stimulus methods

Seim,

Chen,

Han

et al. 2023

Front. Hum. Neurosci.

View full text Add to dashboard Cite

BackgroundPrior work suggests that vibratory stimulation can reduce spasticity and hypertonia. It is unknown which of three predominant approaches (stimulation of the spastic muscle, antagonist muscle, or cutaneous regions) most reduces these symptoms.ObjectiveDetermine which vibrotactile stimulation approach is most effective at reducing spastic hypertonia among post-stroke patients.MethodsSham-controlled crossover study with random assignment of condition order in fourteen patients with post-stroke hand spasticity. All patients were studied in four conditions over four visits: three stimulation conditions and a sham control. The primary outcome measure was the Modified Ashworth Scale, and the secondary outcome measure was the Modified Tardieu Scale measured manually and using 3D motion capture. For each condition, measures of spastic hypertonia were taken at four time points: baseline, during stimulation, after stimulation was removed, and after a gripping exercise.ResultsA clinically meaningful difference in spastic hypertonia was found during and after cutaneous stimulation of the hand. Modified Ashworth and Modified Tardieu scores were reduced by a median of 1.1 (SD = 0.84, p = 0.001) and 0.75 (SD = 0.65, p = 0.003), respectively, during cutaneous stimulation, and by 1.25 (SD = 0.94, p = 0.001) and 0.71 (SD = 0.67, p = 0.003), respectively, at 15 min after cutaneous stimulation. Symptom reductions with spastic muscle stimulation and antagonist muscle stimulation were non-zero but not significant. There was no change with sham stimulation.ConclusionsCutaneous vibrotactile stimulation of the hand provides significant reductions in spastic hypertonia, compared to muscle stimulation.Clinical trial registrationwww.ClinicalTrials.gov, identifier: NCT03814889.

show abstract

Burden of spasticity among patients and caregivers: Results of a multinational survey

Cited by 2 publications

References 0 publications

A Cost-Effectiveness and Budget Impact Analysis of AbobotulinumtoxinA in Greece

A Cost-Effectiveness and Budget Impact Analysis of AbobotulinumtoxinA in Greece

Relief of post-stroke spasticity with acute vibrotactile stimulation: controlled crossover study of muscle and skin stimulus methods

Contact Info

Product

Resources

About